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Abstract
Background: The aim of this study was to evaluate the long-term efficacy and tolerability of
etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients.
Methods: A double-blind, randomized, multicenter study was conducted in 617 patients with OA
of the knee. The base study was 14 weeks in duration and consisted of 2 parts; in Part I (6 weeks),
patients were allocated to once daily oral etoricoxib 5, 10, 30, 60, 90 mg or placebo. In Part II (8
weeks); the placebo, etoricoxib 5 and 10 mg groups were reallocated to etoricoxib 30, 60, or 90
mg qd or diclofenac 50 mg t.i.d. Treatment was continued for consecutive 12 and 26 week
extensions. Primary efficacy endpoints were the WOMAC VA 3.0 pain subscale and investigator
global assessment of disease status. Safety and tolerability were assessed by collecting adverse
events throughout the study.
Results: Compared with placebo, the etoricoxib groups displayed significant (p < 0.05), dose-
dependent efficacy for all primary endpoints in Part I; efficacy was maintained throughout the 52
weeks of the study. During the 46-week active-comparator controlled period, the etoricoxib
groups demonstrated clinical efficacy that was similar to that of diclofenac 150 mg and was generally
well tolerated, with a lower incidence of gastrointestinal (GI) nuisance symptoms compared with
diclofenac (13.1, 14.7, and 13.5% for etoricoxib 30, 60, and 90 mg, respectively compared with
22.5% for diclofenac).
Conclusion: In this extension study, etoricoxib, at doses ranging from 30 to 90 mg, demonstrated
a maintenance of significant clinical efficacy in patients with OA through 52 weeks of treatment.
Etoricoxib displayed clinical efficacy similar to diclofenac 150 mg and was generally well tolerated.
Background
Osteoarthritis (OA) is a disorder that involves softening
and disintegration of articular cartilage, vascular conges-
tion and increased osteoblastic activity in the subarticular
bone, new bone or cartilage growth at the joint margins,
and capsular fibrosis. These factors often lead to pain, a
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common complaint among patients with OA. Other com-
plaints include stiffness, swelling, deformation, and loss
of function in affected joints. Appropriate treatment of
OA is important in maintaining patients' mobility and
overall quality of life as the disorder can lead to severe
functional impairment and disability [1,2].
Patients with OA are commonly treated with analgesic
agents that inhibit the cyclooxygenase (COX) enzymes.
These treatments include nonselective nonsteroidal anti-
inflammatory drugs (NSAIDs) and COX-2 selective inhib-
itors [3]. Two COX isoforms, COX-1 and COX-2, are rec-
ognized; NSAIDs and COX-2 selective inhibitors exert
their analgesic action by inhibiting COX-2 while inhibi-
tion of COX-1 can lead to gastrointestinal (GI) toxicity.
Etoricoxib is a COX-2 selective inhibitor with anti-inflam-
matory and analgesic efficacy comparable to nonselective
NSAIDs in a number of disease and treatment settings [4].
In a previously reported, 2-part, 14-week placebo and
active comparator controlled trial, etoricoxib demon-
strated clinical improvement that was significantly supe-
rior to placebo and similar to diclofenac 50 mg tid [5].
Two consecutive study extensions were conducted follow-
ing the base study for a total of 52 weeks of treatment. The
purpose of this report is to evaluate the maintenance of
efficacy and tolerability of etoricoxib over 52 weeks of
treatment.
Methods
This study (Protocol 007) was conducted in 55 centers in
the United States. The study protocol and procedures were
approved by local Institutional Review Boards of each
study center. All patients gave written informed consent
prior to participation in the original study and before con-
tinuation in each study extension.
Entry criteria
Eligible patients for the base study were a minimum of 40
years old and had both clinical and radiographic evidence
of OA of the knee with symptoms for at least 6 months
prior to study entry, and met American Rheumatism Asso-
ciation (ARA) functional class I, II or III. All patients
required NSAID therapy for 25 of the 30 days prior to the
screening and were required to meet predefined clinical
flare criteria in order to be eligible for allocation [5].
Patients were eligible for the extension studies if they suc-
cessfully completed the original base study, and they had
to have completed the first extension without protocol
violation to be eligible for the second extension.
Exclusion criteria for the base study included: significant
renal impairment (calculated creatinine clearance <30
mL/min); clinically significant abnormalities on screen-
ing physical or laboratory examinations; class III/IV
angina or uncontrolled congestive heart failure; uncon-
trolled hypertension; stroke or a transient ischemic attack
within 2 years; active hepatic disease; a history of recent
neoplastic disease, acute meniscal injury to the study joint
within 2 years of study entry; arthroscopy in the study
joint within 6 months of study entry; weight in excess of
280 pounds (120 kg) or allergy to acetaminophen or con-
ventional NSAIDs. Patients were also excluded if they
required systemic corticosteroids, warfarin, low-dose aspi-
rin or ticlopidine, or if they had required intra-articular
steroids for joints other than the study joint within the
month prior to study entry or to the study joint in the 2
months prior to study entry. For the extension periods
reported here, patients who experienced an AE that led to
discontinuation from study therapy during a previous
treatment period or were considered protocol violators
were excluded from participation.
Study design
The base study was a 2-part, 14-week, parallel-group study
which was followed by 2 consecutive, double-blind,
active-comparator-controlled extensions (12 and 26
weeks, respectively). Part I of the base study was placebo-
controlled; part II and the 2 extensions were active-com-
parator controlled. The base study was conducted to
define the clinically active dose range of etoricoxib in
patients with OA; the extension studies were conducted to
evaluate the safety, tolerability and observe the efficacy of
etoricoxib over an additional 38 weeks. With the base and
extension studies, patients could have participated for a
total of up to 52 weeks.
Following discontinuation of previous therapy and a sub-
sequent flare of clinical OA symptoms, eligible patients
with OA of the knee were randomized to receive placebo,
etoricoxib 5, 10, 30, 60, or 90 mg daily for 6 weeks (part
I) according to a computer generated allocation schedule.
Patients continued in Part II for an additional 8 weeks in
which patients who were on placebo, etoricoxib 5, or 10
mg were given diclofenac 150 mg or etoricoxib 30 mg.
Additionally, 50% of patients who were on etoricoxib 30
mg in part I continued on the same treatment while the
other 50% were given etoricoxib 60 mg. Similarly, 50% of
patients on etoricoxib 60 mg in part I continued on the
same treatment while the other 50% were given etoricoxib
90 mg. Patients taking etoricoxib 90 mg in Part I contin-
ued on the same treatment (Figure 1). Upon completion
of the 14 week base study, patients continued to receive
the same treatment throughout the extension studies as in
Part II (Figure 1). The treatment groups for Part I and II
and all subsequent extensions were pre-assigned at rand-
omization; blinding of patients and study staff was main-
tained throughout [5].BMC Musculoskeletal Disorders 2005, 6:58 http://www.biomedcentral.com/1471-2474/6/58
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Efficacy and safety assessments
The efficacy data reported here are for the 46-week active
comparator controlled period (Weeks 6 to 52), during
which efficacy assessments were made at Treatment
Weeks 6, 8, 14, 20, 26, 34, 42, and 52. However, the effi-
cacy over the entire 52-week period (base study and exten-
sion period) is also shown to assess the maintenance of
effect over the entire treatment period for the subset of
patients who received the same treatment for the entire
52-week period. Efficacy was evaluated using the follow-
ing two primary endpoints for the active comparator con-
trolled period: the Western Ontario and McMaster
Universities OA index (WOMAC) VA 3.0 Pain Subscale
(100 mm Visual Analog Scale [VAS] ;0 = no pain and 100
= extreme pain) and Investigator Global Assessment of
Disease Status (0 – 4 point scale; where 0 = very well and
4 = very poor).
Safety and tolerability data reported here are also from the
active-comparator controlled period for patients received
the same study medication for up to 46 weeks, Week 6 to
52. As with efficacy, safety evaluations were made at study
visits on Treatment Weeks 6, 8, 14, 20, 26, 34, 42, and 52.
Vital signs were monitored at each of these visit. Labora-
tory studies including a complete blood count (CBC),
serum chemistry panel, and urinalysis were performed at
each visit. Clinical and laboratory AEs were recorded
throughout the study; the investigator assessed the rela-
tion of AEs to study medication, the outcome of the AE,
and any action taken. Identification and evaluation of AEs
by the investigator, including those deemed to be "seri-
ous" according to regulatory definitions, were done while
still blinded to study treatment.
Statistical analysis
Treatment response was assessed mainly through inter-
pretation of graphical presentations. For each efficacy
endpoint, these graphs represented the least-squares
mean (LS Mean) changes from baseline and the corre-
sponding standard errors at each time point. LS mean
changes were estimated from an analysis of covariance
(ANCOVA) model with treatment sequence as the main
factor and baseline value (at the Flare/Randomization
Visit) as a covariate. The efficacy analyses were based on a
modified intention-to-treat principle where all patients
who entered the first extension, had a baseline value and
at least one post-baseline measurement in the analysis
period were included. For efficacy, missing values were
imputed by the last value measured prior to that visit (last-
value-carried-forward method). However, the efficacy val-
ues measured in part II of the base study were not carried
forward to the first extension. The two extensions were
assessed as one continuous treatment period, and all
patients who entered the first extension were included in
the efficacy and safety analyses.
The maintenance of efficacy over 52 weeks was evaluated
based upon the subgroup of patients who received the
same treatment and dose throughout the entire study (i.e.
from the start of the base study to the end of the extension
studies, which include only patients taking etoricoxib 30,
60, and 90 mg over 52 weeks). The LS mean changes from
baseline (observed value at the Flare/Randomization visit
of the base study) were plotted and tabulated for these 3
subgroups of patients from the Screening Visit to Week
52.
The following AEs were prespecified for evaluation:
patients with one or more clinical AEs; drug-related clini-
cal AEs; serious clinical AEs (i.e. any AE that results in
death, is life threatening, results in persistent or significant
disability, prolongs an existing inpatient hospitalization,
or any event that jeopardizes the patient based on appro-
priate medical judgment); clinical AEs resulting in discon-
tinuation of therapy; digestive system AEs (including
abdominal pain) resulting in discontinuation of therapy;
lower extremity edema AEs; discontinuations due to lower
extremity edema AEs; hypertension AEs resulting in dis-
continuation of therapy; and AEs related to congestive
heart failure, pulmonary edema, or cardiac failure. GI nui-
sance symptoms (i.e. abdominal pain, acid reflux, dyspep-
sia, epigastric discomfort, heartburn, nausea, and
Study Design Figure 1
Study Design. The patient flow during the entire 52-week 
period is illustrated. The efficacy and safety evaluation for 
this report is based on data from the 46-week active-compa-
rator controlled period.
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vomiting), adverse experiences that are common among
patients who use nonselective NSAIDs, were examined.
Also, laboratory parameters that were prespecified for
evaluation included hemoglobin, hematocrit, alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), and serum creatinine.
Results
There were 617 patients enrolled into the base study. Of
these 617 patients, 550 patients entered part II (the begin-
ning of the active-comparator controlled period) and 427
patients completed Part II and entered the first extension.
Among the 550 patients who entered the active compara-
tor controlled period, 198, 102, 148, and 102 patients
received 30, 60, and 90 mg etoricoxib daily and 50 mg
diclofenac three times daily, respectively. At randomiza-
tion, there were no clinically meaningful differences in
baseline characteristics between the treatment groups
(Table 1). The mean age was 62 years, 72% of the patients
were women, and mean duration of OA of the knee was
7.4 years. During the active comparator controlled period,
the most common reasons for discontinuation were clin-
ical AEs (Figure 2).
Efficacy
Over the 46-week active comparator controlled period,
etoricoxib 30, 60, and 90 mg had similar efficacy com-
pared with diclofenac 150 mg (Figure 3). For both pri-
mary efficacy endpoints, the degree of clinical
improvement relative to baseline was at or above the level
of clinical importance, which was defined as 10 mm on
the VAS WOMAC Pain Subscale or 0.5 Likert units on the
Investigator Global Assessment of Disease Status [5]. Fur-
thermore, this degree of improvement was maintained at
a relatively constant level during the two extension peri-
ods for all active treatment groups (Figure 3).
To demonstrate the consistency of efficacy in patients on
the same etoricoxib treatment over the 52-week treatment
period, results for the subset of patients who received the
same treatment for the entire 52-week period are also pro-
vided (Figure 4). The maximal treatment effect was
reached during the base study at the end of Week 6 for the
30, 60, and 90 mg etoricoxib groups and maintained
throughout the 52-week treatment period for the two pri-
mary endpoints, with small differences in efficacy favor-
ing the 60 mg group [5].
Safety
During the 46-week active-comparator controlled period,
etoricoxib 30, 60, and 90 mg and diclofenac 150 mg were
generally well tolerated, consistent with previously
reported results for Part 1 of the base study (Table 2). The
incidence of clinical AEs was similar among the treatment
groups. Clinical AEs determined by the investigator
(blinded) to be possibly, probably, or definitely drug-
related were slightly greater in the etoricoxib 90 mg and
diclofenac 150 mg groups (23.0% and 24.5%, respec-
tively) compared with etoricoxib 30 mg (17.2%) and etor-
icoxib 60 mg (17.6%). More patients in the diclofenac
Table 1: Baseline Patient Characteristics at Randomization (Patients Entering the Active Comparator Controlled Period – Weeks 6–
52)
Etoricoxib Diclofenac
30 mg 60 mg 90 mg 150 mg
(N = 198) (N = 102) (N = 148) (N = 102)
n (%) n (%) n (%) n(%)
Gender
Female 141 (71.2) 75 (73.5) 100 (67.6) 79 (77.5)
Male 57 (28.8) 27 (26.5) 48 (32.4) 23 (22.5)
Mean age in years (SD) 61.9 (10.4) 62.3 (10.2) 60.6 (9.6) 62.3 (10.4)
Race
White 176 (88.9) 89 (87.3) 131 (88.5) 93 (91.2)
Black 15 (7.6) 6 (5.9) 10 (6.8) 6 (5.9)
Hispanic 7 (3.5) 5 (4.9) 7 (4.7) 2 (2.0)
Native American 0 (0.0) 2 (2.0) 0 (0.0) 1 (1.0)
Mean Duration of OA in years (SD) 7.8 (7.9) 7.5 (6.6) 7.8 (7.4) 7.5 (7.1)
ARA Function Class
Class I 25 (12.6) 12 (11.8) 25 (18.6) 19 (18.6)
Class II 134 (67.7) 72 (70.6) 95 (65.7) 67 (65.7)
Class III 39 (19.7) 18 (17.6) 27 (18.4) 16 (15.7)
WOMAC Pain Subscale (100 mm VAS† [Mean (SD)] 68.4 (17.0) 68.2 (17.7) 67.7 (16.9) 69.8 (16.1)
Investigator Global Assessment of Disease Status (0 to 4 
Likert Scale) [Mean (SD)]
2.9 (0.6) 2.8 (0.7) 2.9 (0.6) 2.8 (0.7)
† 0 to 100 mm Visual analogue scale.BMC Musculoskeletal Disorders 2005, 6:58 http://www.biomedcentral.com/1471-2474/6/58
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group discontinued due to an AE (11.8%) compared with
the etoricoxib groups (3.0 to 6.8%).
A higher percentage of patients in the diclofenac group
had GI nuisance symptoms (26.6%) than in the etori-
coxib groups (16.5%, 16.7%, and 14.9% in the 30, 60,
and 90 mg etoricoxib groups, respectively). Consistent
with this, the percent of patients who discontinued due to
these GI nuisance symptoms was higher in diclofenac
(4.0%) than in the etoricoxib groups (0.0%, 1.0%, and
2.1% in the 30, 60, and 90 mg etoricoxib groups, respec-
tively; Table 2). One patient (etoricoxib 90 mg) had a gas-
tric ulcer during the 52 week period. This patient had a
prior history of esophagitis and gastric erosion. There
were no other reports of patients with GI perforations,
ulcers, or bleeding events.
Lower extremity edema was reported for 4.5, 3.9, and
3.4% in the 30-, 60-, and 90-mg etoricoxib groups, respec-
tively and 2.0% in the diclofenac group. There was evi-
dence for a dose-related trend in the proportion of
patients with hypertension: 2.0, 2.9, and 5.4% in the 30,
60, and 90 mg etoricoxib groups, respectively and 4.9% in
the diclofenac group. One patient in the etoricoxib 30 mg
group discontinued due to lower extremity edema and
one patient in each of the following treatment groups dis-
continued due to hypertension: etoricoxib 30 and 90 mg
and diclofenac. One patient (etoricoxib 60 mg) who had
an AE that consisted of mild congestive heart failure and
was felt by the investigator to not be drug related, contin-
ued on the study and recovered.
There was one confirmed CV thrombotic event during the
active-comparator controlled period; a cerebrovascular
accident occurred in a patient taking diclofenac 150 mg.
The event was deemed to not be drug-related and the
patient was discontinued from the study after being put
on low-dose aspirin therapy (an excluded medication).
Laboratory AEs were reported for 5.6, 5.0, 9.6, and 18.6%
in the 30, 60, and 90 mg etoricoxib and 150 mg diclofenac
groups, respectively during the active-comparator control-
led period (Table 3). Drug-related laboratory AEs were
reported for 2.0, 0.0, 4.1, and 11.8 % in the 30, 60, and 90
mg etoricoxib and 150 mg diclofenac groups, respectively.
The most frequently reported laboratory AEs were
increased levels of ALT and AST, which accounted for
much of the higher incidence of laboratory AEs in the
diclofenac group. Elevated levels of these enzymes were
reported in a greater percent of patients in the diclofenac
group (10.8%) versus the etoricoxib groups (1.0 to 2.1%)
(Table 3). Three patients on diclofenac discontinued due
to ALT/AST increases compared with no patients in the
etoricoxib group. The largest change from baseline in ALT
was observed at Week 20 in the diclofenac group (42.4%).
Mean ALT decreased in subsequent weeks in the
diclofenac group (6.6% above baseline at Week 52). Mean
AST was also higher in the diclofenac group vs. the etori-
coxib groups, but decreased over time. Two patients on
etoricoxib (1 in the 30 mg group and 1 in the 90 mg
group) and one patient on diclofenac 150 mg discontin-
ued due to an increase in serum creatinine. Serum creati-
nine returned to baseline following discontinuation of
study medication in these three patients.
In addition to the analysis of patients during the active-
comparator controlled period, safety data is presented
showing rates of most common AEs and AEs of special
interest (GI and renovascular AEs) per 100 patient-years
for all patients treated with etoricoxib 30, 60, or 90 mg or
diclofenac in either the placebo-controlled or active com-
parator-controlled periods (this includes patients that
Patient accounting Figure 2
Patient accounting. † Number represents any patient who dis-
continued during the active comparator controlled period. 
Percent is calculated using the number of patients that 
entered the first extension as the denominator. ‡ Other Rea-
sons include lost to follow-up, patient moved, patient with-
drew consent, or protocol deviation.
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received a different treatment during the placebo-control-
led period) (Table 4). The AEs occurring at the highest rate
were upper respiratory infection, headache, and diarrhea.
Lower extremity edema occurred at a higher rate in the
etoricoxib groups compared with diclofenac. Hyperten-
sion occurred at a higher rate in the etoricoxib 90 mg and
diclofenac groups compared with the etoricoxib 30 mg
and 60 mg groups.
Discussion
Etoricoxib 30, 60 and 90 mg demonstrated clinical effi-
cacy in patients with OA in the first 6 weeks of therapy [5];
this level of efficacy was maintained during the 46-week
active comparator controlled period. The magnitude of
improvement observed with the etoricoxib 60 and 90 mg
groups was similar to that of the diclofenac group; the effi-
cacy demonstrated by the etoricoxib 60 and 90 mg groups
was slightly greater than that observed with the etoricoxib
30 mg group. This was most evident in the efficacy evalu-
ation of patients treated with the same dose of etoricoxib
from the beginning of the study through the second exten-
sion. All treatments were generally well tolerated and no
new or unique findings related to safety or tolerability
were revealed during long-term dosing of etoricoxib (i.e.,
over 52 weeks).
Patients who received the same dose of etoricoxib from
the beginning of the base study through the second exten-
sion demonstrated that, generally, the treatment effect
reached a plateau at approximately week 6 of therapy; the
treatment effect was maintained at that level through
week 52 of the study.
In the placebo-controlled period (part I) of the base study,
the treatment responses of etoricoxib 30 mg were signifi-
cantly greater than that of placebo, but were approxi-
mately one-half to two-thirds of that of etoricoxib 60 mg
as assessed by the primary endpoints. Etoricoxib 60 and
90 mg provided similar efficacy, indicating that the 60 mg
dose was the minimal dose with maximal efficacy [5].
During the extension studies, however, patients who con-
tinued on the 30 mg dose had a treatment response that
more closely approximated that of the 60 mg and 90 mg
doses; the treatment effect for all treatment groups was
maintained for up to 52 weeks. Furthermore, the treat-
ment effect with etoricoxib (30, 60 and 90 mg) was simi-
lar to that of diclofenac 150 mg. These results should be
interpreted cautiously as the number of patients in each of
the treatment groups was relatively small and decreased
over time due to discontinuations from the study.
Both etoricoxib and diclofenac appeared to be well-toler-
ated. However, patients in the etoricoxib group experi-
Primary efficacy endpoints from during the active comparator controlled period (weeks 6 to 52) Figure 3
Primary efficacy endpoints from during the active comparator controlled period (weeks 6 to 52). This is a comparison of etor-
icoxib 30, 60, and 90 mg with diclofenac 150 mg during the active comparator controlled extension periods. LS Mean Change 
from Baseline (Randomization) is shown. Modified intention-to-treat approach with last value carried forward was used. The 
number of patients at later visits (≥34 weeks) was small. Data should, therefore, be interpreted with caution. SE = Standard 
error.   = 30 mg etoricoxib;   = 60 mg etoricoxib;   = 90 mg etoricoxib;   = 150 mg diclofenac.
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enced fewer GI nuisance symptoms during the extensions.
A larger proportion of patients in the diclofenac group dis-
continued due to these GI nuisance symptoms. In 8 previ-
ous clinical trials, less patients on etoricoxib discontinued
due to a GI symptom vs. comparator nonselective NSAIDs
[6]. In one randomized controlled trial, patients receiving
etoricoxib had less fecal blood loss versus ibuprofen and
in another trial, etoricoxib patients had fewer endoscopi-
cally detectable lesions versus naproxen; these data sug-
gest that etoricoxib may be associated with a reduced
incidence of GI perforations, ulcers, or bleeds (PUBs) [7].
Additionally, in a large clinical trial, etoricoxib 90 mg
demonstrated a superior GI tolerability profile compared
with diclofenac 150 mg; there were significantly fewer
patients on etoricoxib that experienced a GI AE versus
diclofenac [8].
There was only one serious thrombotic cardiovascular
(CV) event during the active comparator-controlled
period, which occurred in a patient receiving diclofenac.
In this study, use of low dose aspirin, which is a factor that
is indicative of CV risk, was not allowed since the study
was initiated before the GI COX-2 hypothesis was proven.
Although aspirin users were excluded from the study,
patients with other cardiovascular risk factors (i.e., chest
pain, hypertension, history of smoking, hypercholestero-
lemia, palpitation, mitral valve prolapse, and sinus brady-
cardia) were allowed in the study.
To assess either GI or CV safety, larger and longer-term tri-
als or pooled analyses are required since the incidence of
such events is relatively rare [9,10]. In a pooled analysis of
the etoricoxib development program, the rate of serious
thrombotic CV events in patients treated with etoricoxib
was not discernibly different than in patients treated with
NSAIDs that are not associated with potent and sustained
antiplatelet effects such as diclofenac and ibuprofen [11].
Although no discernible difference was observed in com-
parison to placebo either, the placebo-controlled throm-
botic CV safety data for etoricoxib are limited in quantity
and in duration to 12 weeks. However, results from
longer-term, placebo-controlled trials with rofeocoxib
and celecoxib suggest that use of COX-2 selective inhibi-
tors are associated with an increased incidence of adverse
CV events compared to placeb [12,13]. Large, long-term
trials to assess the CV safety profile of etoricoxib are ongo-
ing.
Renovascular effects were also examined during the 52-
week treatment period since NSAIDs and COX-2 selective
inhibitors can affect renal physiology [14,15]. In the base
study, there was a small number of renovascular AEs;
most common with the 90-mg dose, minimal with the 60-
mg dose, and not detectable with 30 mg etoricoxib [5].
Overall, renovascular effects were of limited clinical sig-
nificance during the active comparator periods. The inci-
dence of congestive heart failure was low (1 event in a
Primary endpoints evaluating efficacy of etoricoxib Figure 4
Primary endpoints evaluating efficacy of etoricoxib. LS Mean Change from Baseline is shown for patients receiving 30, 60 or 90 
mg etoricoxib for up to 52 weeks. Modified Intention-to-Treat Approach With Last Value Carried Forward was performed. As 
the numbers of patients were small and decreased over time, data should be interpreted with caution. Screening (S) to baseline 
(R) = NSAID washout period; SE = Standard error ❍  = 30 mg etoricoxib; * = 60 mg etoricoxib; ◆  = 90 mg etoricoxib.
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Table 2: Clinical Adverse Experience Summary During the Active-Comparator Period (Weeks 6–52)
Etoricoxib 30 mg Etoricoxib 60 mg Etoricoxib 90 mg Diclofenac 150 mg
(N = 198) (N = 102) (N = 148) (N = 102)
n (%) n (%) n (%) n (%)
Clinical Adverse Experiences (AEs)
All Clinical AEs 136 (68.7) 73 (71.6) 112 (75.7) 81 (79.4)
Drug-related Clinical AEs† 34 (17.2) 18 (17.6) 34 (23.0) 25 (24.5)
Serious AEs 12 (6.1) 3 (2.9) 5 (3.4) 7 (6.9)
Discontinued due to an AE 6 (3.0) 6 (5.9) 10 (6.8) 12 (11.8)
Most Common Clinical AEs *‡
Dizziness 6 (3.0) 6 (5.9) 6 (4.1) 1 (1.0)
Influenza-Like Disease 14 (7.1) 6 (5.9) 4 (2.7) 3 (2.9)
Upper Respiratory Infection 32 (16.2) 14 (13.7) 28 (18.9) 21 (20.6)
Diarrhea 12 (6.1) 1 (1.0) 7 (4.7) 13 (12.7)
Heartburn 6 (3.0) 5 (4.9) 7 (4.7) 6 (5.9)
Nausea 8 (4.0) 5 (4.9) 4 (2.7) 6 (5.9)
Headache 10 (5.1) 6 (5.9) 1 (0.7) 3 (2.9)
Urinary Tract Infection 10 (5.1) 3 (2.9) 5 (3.4) 5 (4.9)
Gastrointestinal (GI) Nuisance Symptoms%
GI Nuisance Symptom AEs% 26 (13.1) 15 (14.7) 20 (13.5) 23 (22.5)
Discontinuations 0 (0.0) 1 (1.0) 2 (1.4) 4 (4.0)
Renovascular AEs
Lower Extremity Edema 9 (4.5) 4 (3.9) 5 (3.4) 2 (2.0)
Discontinuations 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)
Congestive Heart failure 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Discontinuations 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypertension 4 (2.0) 3 (2.9) 8 (5.4) 5 (4.9)
Discontinuations 1 (0.7) 0 (0.0) 1 (0.8) 1 (1.2)
†Determined by the investigator to be possibly, probably, or definitely related to treatment
* Incidence 5.0% or more in any treatment group
‡ Hypertension is among the most common AEs, but is listed under the Renovascular AEs section of the table.
%Includes abdominal pain, acid reflux, dyspepsia, epigastric discomfort, heartburn, nausea, and vomiting
Table 3: Laboratory Adverse Experience Summary During the Active-Comparator Period (Weeks 6–52)
Etoricoxib 30 mg Etoricoxib 60 mg Etoricoxib 90 mg Diclofenac 150 mg
(N = 197) (N = 101) (N = 146) (N = 102)
n (%) n (%) n (%) n (%)
Laboratory AEs
Patients with one or more laboratory AEs 11 (5.6) 5 (5.0) 14 (9.6) 19 (18.6)
With drug-related adverse experiences† 4 (2.0) 0 (0.0) 6 (4.1) 12 (11.8)
With serious adverse experiences 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to laboratory AEs 1 (0.5) 0 (0.0) 1 (0.7) 5 (4.9)
Laboratory AEs of special interest
Alanine Aminotransferase Increased (ALT) 3 (1.5) 1 (1.0) 3 (2.1) 11 (10.8)
Aspartate Aminotransferase Increased (AST) 2 (1.0) 1 (1.0) 2 (1.4) 11 (10.8)
Hemoglobin Decreased 1 (0.5) 0 (0.0) 1 (0.7) 3 (2.9)
Hematocrit Decreased 1 (0.5) 0 (0.0) 1 (0.7) 1 (1.0)
Serum Creatinine Increased 1 (0.5) 1 (1.0) 2 (1.4) 2 (2.0)
†Determined by the investigator to be possibly, probably, or definitely related to treatmentBMC Musculoskeletal Disorders 2005, 6:58 http://www.biomedcentral.com/1471-2474/6/58
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patient receiving etoricoxib 60 mg) and the incidence of
hypertension with etoricoxib was generally similar to that
of diclofenac, although the number of hypertension
events was dose-related. The risks for renovascular effects
in prior trials of the etoricoxib clinical development pro-
gram were low with a shallow dose response and were
generally similar to those found with naproxen or ibupro-
fen [16].
Conclusion
In summary, etoricoxib once daily provided a clinical
effect that was similar to that of diclofenac 150 mg in
patients with OA and was maintained for up to 52 weeks.
In the base study [5], etoricoxib 60 mg was the minimal
dose with maximal efficacy; however, in this extension
study, all thee doses of etoricoxib, including 30 mg, pro-
vided robust efficacy that was maintained for up to 52
weeks. All treatments were generally well tolerated over 52
weeks. These data support the role of etoricoxib as an
important long-term treatment option for the manage-
ment of patients with OA.
List of abbreviations
Abbreviation Definition
OA Osteoarthritis
COX Cyclooxygenase
NSAID Nonsteroidal anti-inflammatory drug
WOMAC Western Ontario and McMaster Universities OA
index VA 3.0 Pain Subscale
VAS Visual Analog Scale
GI Gastrointestinal
CV Cardiovascular
AE Adverse experience
ALT Alanine aminotransferase
Table 4: Rates of Adverse Experiences (AEs) of Special Interest per 100 Patient-YearsAll Patients Over The Entire 52 Weeks From 
The Start of Therapy to the End of the Period
Etoricoxib Diclofenac
30 mg 60 mg 90 mg 150 mg
n (rate†)n  ( r a t e †)n  ( r a t e †)n  ( r a t e †)
Most Common Clinical AEs*
Diarrhea 20 (15.4) 9 (12.2) 14 (13.4) 14 (23.2)
Dizziness 9 (6.9) 8 (10.8) 9 (8.6) 1 (1.7)
Dyspepsia 8 (6.1) 3 (4.1) 5 (4.8) 8 (13.3)
Headache 19 (14.6) 18 (24.4) 4 (3.8) 4 (6.6)
Influenza-like disease 18 (13.8) 7 (9.5) 6 (5.8) 4 (6.6)
Lower Extremity Edema 11 (8.4) 9 (12.2) 7 (6.7) 2 (3.3)
Nausea 14 (10.7) 9 (12.2) 10 (9.6) 7 (11.6)
Rash 6 (4.6) 10 (13.5) 4 (3.8) 1 (1.7)
Sinusitis 15 (11.5) 5 (6.8) 14 (13.4) 5 (8.3)
Upper Respiratory Infection 45 (34.5) 31 (42.0) 41 (39.3) 26 (43.1)
GI Nuissance Symptoms
Abdominal pain 11 (8.4) 4 (5.4) 2 (1.9) 5 (8.3)
Acid reflux 0 (0) 0 (0) 0 (0) 1 (1.7)
Dyspepsia 8 (6.1) 3 (4.1) 5 (4.8) 8 (13.3)
Epigastric discomfort 4 (3.1) 1 (1.4) 6 (5.8) 2 (3.3)
Heartburn 7 (5.4) 7 (9.5) 9 (8.6) 6 (9.9)
Nausea 14 (10.7) 9 (12.2) 10 (9.6) 7 (11.6)
Vomiting 3 (2.3) 1 (1.4) 0 (0) 1 (1.7)
Renovascular AEs
Lower extremity edema 11 (8.4) 9 (12.2) 7 (6.7) 2 (3.3)
Congestive heart failure 0 (0) 2 (2.7) 0 (0) 0 (0)
Hypertension 7 (5.4) 4 (5.4) 10 (9.6) 5 (8.3)
*Rate ≥ 10% in any group
† Rate per 100 patient years of exposure = (# of AEs / Patient Years)
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AST Aspartate aminotransferase
ARA American Rheumatism Association
CBC Complete blood count
LS Least squares
ANCOVA Analysis of covariance
PUB Perforation, ulcer, or bleed
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